SYNH - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Syneos Health Second Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time.

I would like to hand the conference over to Ronnie Speight, Senior Vice President of Investor Relations. Please go ahead, sir.

Ronnie Speight

everyone. morning, Good our the Executive on Michelle are MacDonald, Paul Alistair our Solutions. With Jason call Meggs, Chief Colvin, and Solutions; Officer; of Officer; of our our Clinical President me Commercial today President Chief Keefe, Financial

statements release, the results, Company our our of These expectations, filings. materially to on under slide presentation at plans, ended purposes about and from obligation are our Risk future investor.syneoshealth.com. the factors the Remarks XXXX, of of statements for growth, update In prepared press corresponding forward-looking differ by and Litigation other Safe is financial indicated remarks prospects results the SEC addition for result Harbor constitute these Private discussed forward-looking a Form the year in to make may disclaim the Reform and section anticipated XX-K available those website to for of Act we Factors that December as we factors. provisions them. our XXXX important any XX, a Actual various Securities

be operations. financial non-GAAP accordance we consider measures with be non-GAAP events core discuss of certain and exclude in a considered to not which to, a this call, replacement our effects During transactions the should will we measures supplement prepared measures, outside of These for GAAP.

measures, For a reconciliation refer to please most GAAP appendix of with the our comparable measures non-GAAP financial directly of presentation. the

over the Alistair turn I Alistair? call to would to like now McDonald.

Alistair MacDonald

for earnings the call. Thank you, day, thank Health Syneos Ronnie. Good XXXX QX and joining everyone, you

growth profitability with segments across midpoint in and guidance second the revenue of fueled in and for strong solutions both the solutions. growth results Our performance clinical commercial our quarter by accelerated exceeded strong for

pipelines. by our integrated development in opportunities customer team. see by growing the generated This clinical strong commercial interest unique to and as evidenced product Syneos continue interest our further is by flow and robust demonstrated RFP We comprehensive market offerings One

key with performance a me highlights. few start Let

solutions X.X% or of in to currency, XX.X% growth of in or or First, currency. was second increased quarter This our in of growth X.X% XXXX. a commercial the clinical compared X.X% constant adjusted solutions X.X% revenue growth accelerated X.X% currency continued by strong constant constant driven

$X.X aggregate commercial with ratio Second, we net of book-to-bill was of X.XXx. X.XXx solid book-to-bill sales and trailing XX-month This an overall for performance of awards X.Xx comprised of clinical the billion the and the had period. book-to-bill of

large our thesis customers of unique services This would are quarter. the subsequent excited is relationship we of were a client integrated announce end to further the clinical our with Third, to This penetration. clinical we and end-to-end preferred one second that model. scale particular created enhance awarded proposition that the pharma already our top-tier and value commercial capabilities our we’ve showcases major largest win adding significant validates provider

our somewhat expect meaningful new to revenue more contribute a We of anticipate this for in awards new contribution in and beyond. business the XXXX and remainder relationships XXXX awards

maintained with our pharma While second provider the strategic comprehensive half first also providing companies XXXX, of top first in this new quarter preferred for since the by strength XXXX This midsize award the clinical small relationship customer secured we've to solutions XX this we’ve of evidenced represents market. compared across combined the and in for to XXXX. is the commercial clinical double-digit segment growth new

our to business. results turning Now by

to a book-to-bill through awards we drive as now net book-to-bill This Clinical of Our the quarterly growth total Solutions we This trailing XX-month X.XXx. quarter for $X in awards continued resulted billion with X.X%, of a period in producing which year-over-year solid growth XXXX. move ratio to brings segment second backlog the X.Xx. achieved of clinical the expect

segment. particularly midsized highlighting in customers, and with our this small were continued awards strength robust quarter core critical second The us

XX-month trailing delivered in a segment Solutions XXXX, X.XXx. resulting during the book-to-bill of quarter, or we second period experienced quarterly billion of for of awards pressure Similar Commercial the seasonal Our in a net book-to-bill X.XXx. to awards $X.X

However, year-over-year Deployment Solutions, backlog growth in XX.X%. Solutions at formerly remain Selling strong

In offer across opportunities, all by commercial customer where comprehensive awarded pipeline our driven certain to addition, from includes diseases. omni-channel ability project customers during novel class to second solutions we quarter of strategic segments. sophisticated a significant for strong our therapies the a developing we have chronic were a offering This biotechnology of

including not the channel analytics This one of XXXX. of integrated for the over is small strategies, center XX% evidence commercial major midsize resources, to further data a science our launch omni-channel but and field contact award and revenue management measurement. we to only key includes This also comprehensive driving year-over-year customer first realize through that into continue program growth segment

Within Commercial of scale of organization. the we class our and the continued of capabilities Solutions, extremely proud are world communications recognition

XXXX market independent medical the communications number of world, the media top magazine. America ranking agencies recognized as business As two North largest was healthcare recently in prestigious in network as part the by focused XXX our business in a the communications

communications experiences and deep patients. Our customer collaborates deliver creative improve for to performance daily differentiated organization including accelerate insights solutions, to behavior

is see and for deploy small a interest customers first alternative integrated an sizes of streamlined capital development timelines. awards unique accelerate our all commercialization to our strong enabling for midsized of provide to continue million $XXX as and positioned in their development infrastructure. This seamless offering We product half Syneos to which offering, XXXX the and ideally One over customers efficiently to influenced of has

driving differentiating element customers growth and also these is large One within a segment investment. ongoing to services area our portfolio in pharma core of strategic model help the as our future Syneos Syneos midsize One optimize management. an look critical unique in This is

therapeutic talent across in we growth our capabilities top as drive to and further We to business look invest market continue development drive segments. also all on

Client integrated commercial years experience across than we lead business global solutions in of and I'm As Lisa announce we clinical last key to customer Global President effort partnerships enhance as strategic globally, To quarter, discussed account addition development, is management. accounts management of ideally and launched new role client function more this the our for Solutions. the of continuum. of to this XX our pleased key suited Rometty bringing Lisa

strengthen will believe Life We Syneos the Organization the to and and team. recently for most awareness growth will and channels introduce new General was Watson innovative models great of Manager Health. House we know relationships, brand addition Oncology She and of Sciences a she IBM drive be she executive

for within Executive Patrick Oncology talent also our the in experience area, therapeutic segment of has while and Global General the addition device insights our team. drug Patrick a our medical as in pharmaceutical, wealth continues Commercial development Top embedding President acquisition critical with the and Clinical Vice Manager and with Solutions. Patrick to operational will this within of Nealon years therapeutic important excellence XX sectors. continue biotech across drive plus growth oncology

recently our biopharmaceutical of celebrated As the the second we the to merger, realize accelerator. continue benefits of we anniversary only end-to-end industry's creating

enhancing thesis our commercial customers. customers, large of sophisticated while our merger through for our penetration offerings our SMID pharma increasing validating We’re integrated

because existing our Importantly, to the relationship new large product ability provide pharma insight and in development with sophisticated clinical of relationship awarded our delivery. highlighted commercial part was seamless

continued performance, marketplace. reinforce and quarter's the unique proposition value in our This further recognition innovation awards

to sharing Health. all again like Syneos employees close by to would my at appreciation I once the

our model to that every from to helping distance day achieves vision lab a our customers shortening deliver are efforts all life. across the to Our better us sectors

on turn financial our let me Now more performance. over Jason? for it comments to Jason

Jason Meggs

morning, Thank you, good everyone. Alistair, and

are as non-GAAP on results on As a X. or Slide defined discussed all an basis reminder, adjusted

discussing reimbursable results XXX comparisons current We period-to-period include and will be ASC the on basis, period adjusted an which expenses.

Let results by in me reviewing our begin financial detail.

constant up accelerated Solutions $X.XX revenue X.X% a remain quarter Solutions As adjusted billion, Commercial in was Clinical and shown of of million. growth of XXXX exchange quarter This up second second segments growth was on the strong. driven both excluding Slide X.X% XXXX when currency for X, to foreign the by headwind our compared as $XX.X and growth

growth constant revenue segment million X.X% constant in Clinical year-over-year over X.X% million Solutions revenue the by expenses, adjusted to was was in and adjusted solid Clinical up offset higher year-over-year of basis. revenue favorable XX.X% mix currency. awards up net Commercial Our to growth and X.X% reimbursable the grew last driven months, $XXX.X FX. by impact a or partially currency on XX revenue $XXX.X

increase points. This was basis of of in Commercial resulting in by the partially impact months exchange FX. includes to an second contemplated XX.X% growth year-over-year, the of the EBITDA impact attributable XX the Kinapse, and preceding growth $XXX.X million, and of an of for a offset over quarter XX increase adjusted largely $X.X expenses in Solutions EBITDA guidance. foreign benefit net was with margin XX.X%, reimbursable Adjusted lower awards the of our consistent acquisition million

and higher associated This growth leverage. revenue improved offset favorable mix, in by overall expenses. related These large reimbursable driven and with increase realized and by of in adjusted net operating partially revenue costs margin relationships synergies the customer growth, new startup in were was benefits growth EBITDA

synergies growth. and EBITDA to of separation in XXX, consistent XXXX drive track our It adjusted target note we more by a points are million margins that the EBITDA This much of annually with is our approximately realization synergies million quarter to on is second aligned during our the $XX reinvestments before under XXXX. also impact closely to includes basis currency important strategic the only constant achieve of ASC for XXX segment of basis. and with remain Adjusted $XXX year-to-date on

by rate. of adjusted EPS in diluted tax EBITDA non-GAAP grew driven and primarily year-over-year, XX.X% growth Adjusted lower by $X.XX our

XXXX. adjusted for Specifically, the our the diluted quarter in improved tax to rate second contributed of $X.XX growth EPS

to the Slide balance flow and on X. cash sheet moving summarized Now as

cash basis. $XXX.X integration we During quarter temporary an to as the improvement an our million reported normalized the previously represents in delays $XX.X highlighted. second cash quarter, million compared on as This for operations provided first related the of flow

DSO XX.X the cash on XXXX. of The outstanding few these quarter to billion. ended the collected, expect delay accounts. the have of $X.XX we a for of of so the quarter decline XXs million been with debt already $XXX.X unrestricted during DSO third of elevated to quarter collections days We large total and majority low was the by

deployment provides cash by This shareholder investments debt as market available well also We balanced acquisitions, activities. our on approach capital drive focused an to deployment as as and debt repayment, capital a remain on X flow repurchases share update and tuck-in opportunities value. to includes and conditions. Slide management determined

During quarter, leaving million tax million an $XX.X of effective perspective, non-GAAP this $XX year. repurchase was our rate of be utilized available XX.X%, of common to consistent our quarter at stock, we for end second repurchased full-year the $XXX.X outstanding remaining XXXX. loans repaid additional tax term the expectations second the for a From our million the our with capacity stock of and

to However, of given $XX deductions, taxes actual the our cash million net our for full-year be million XXXX. of outlay only to for $XX NOL the benefit expect we

and testing have that We in year. completed weaknesses will have report as material to pleased our remediation disclosed internal this previously process, the evaluation although focus continued also final largely and annual internal of control our teams we later remediation order certification to I'm controls. on believe occur of part our process

investigation continue or ultimate also resolution. SEC to relates regarding developments the the XXXX, fully of We to it quarter the cooperate we first in disclosed that timeline as report have with information no new for additional any the to

guidance to our Turning X. on now Slide

updating of comprised to of of adjusted are adjusted $X.XX of XXXX We to X.X% growth range of of to $X.XX to for of representing the to X.X%. our billion, $X.XX X.X% $X.XX clinical the billion, revenue to growth growth X.X% X.X% billion revenue is adjusted expectations to XX.X%. or $X.XX revenue of $X.XX commercial billion billion full-year and billion representing This

X.X% and from between adjusted million million XX.X%. to total $XXX range EBITDA expect to We growing $XXX

the reflects by in second share full-year Lastly, This year-to-date with that $X.XX, and of driven EPS we our our consistent expect results is quarter growth repurchases. adjusted representing with performance updated expectations to $X.XX guidance diluted half guidance XX.X%. second X.X% range of prior to

million million based the the rate estimated which of current is interest interest and our of vary expected backlog guidance prior any shares, reinvestments, $XXX million, will trends to in share of quarter. expense synergies of and our count XXX.X pipeline $XXX subsequent excludes sales estimated to non-GAAP currency $XXX key This merger share in exchange and repurchases expected to on quarter-by-quarter following cancellations million rates existing resulting XX% foreign including assumptions: delays, rates, and second our $XXX to million diluted tax XX% to

growth to provide for some want you quarter, also I XXXX the with commentary expected our third profile. given

adjusted We comprised This X.X% $X.XX to adjusted expect and billion, growth of of X.X%. of commercial of to representing growth revenue revenue to X.X%. revenue of X.X% to growth $X.XX billion adjusted is X.X% X.X% clinical year-over-year

to $XXX growth We expect total adjusted X.X%. million EBITDA $XXX year-over-year of of to representing million, X%

updated When guidance last highlighted normalizing at reflex in we adjusted these year, our for EBITDA of margin $X of expansion we the midpoint. basis quarter. XXXX benefits XXXX quarter the items, for of include third As adjusted in EBITDA million of fourth originally quarter the a the expected that third points XX

answer Operator? we'd prepared happy This any to and remarks, be completes our questions.

Operator

[Operator from you. comes Sachs. Instructions] question Goldman first Thank Jones And Robert our with

open. is line Your

Robert Jones

competitive go commercial client, any Great. Thanks more large clinical on questions. Alistair, the I side guess, came that the the mentioned win a strategic legacy you historically back that little for just just there. to outsource it detail were just of about? looking Was the a that for from bit to of a they providers, a process, or RFP get using to clinical other it better opportunity and how currently came trying size of sense

Alistair MacDonald

scale. as last guys morning, processes a a that of basis work end. in both of commercial before the so on that large CRO big big customer that you transactional because we to between not imperatives was a that we've Competitive were really have I and Yes, for the large the with a but these opportunities, months customer now. the on compete be more to all time a That of indexed pharma have commercial top player requisite Good Bob. think process last I organizations and think in to create done long a factor major was Thank big right us Yes. know, And clinical of those you. under basis. side several scale for process kind in for scale clinically, legacy about was combination kind

that end a XXXX kind off revenue So driving we into XXXX. there, critical see of starting over awards the something see towards also as of but win, that we

of We a that space to some in are dislodged table. pleased take competitors very and at that to that seat

Robert Jones

the the the be the that about one guess probably throughout on should eroding year, then on the Sequential conversion with other the more That’s went communication helpful. improvement And to conversion. previous I compared I just follow-up if side, I backlog clinical could obviously thinking we rate think way.

that think conversion the what drove over Just and then potentially we continuing curious, how year? should accelerate the of kind of to about that balance

Jason Meggs

Bob. Yes. Jason. Hi, Thanks. This is

the the we quarters little you’re conversion that did the look quarter and a during quarter last that quarter the revenue of and did burn range always at the bit laid had projects out QX, we So push first had you helps look flattish to QX similar X%. it we timing couple that range be through backlog the startup items also with some and When would given, instead the business are we’ve ahead. nice of mentioned a of and that that second in the it getting during we the the rate. be out in felt come through XX. second going come sort in a job, like we of process you of at half, guidance if The

see do timing the came we bit a the quarter. So it in through given normalizing items that

Robert Jones

much. so Thanks Great.

Alistair MacDonald

Thanks, Bob.

Operator

Thank you.

Our Windley question next from comes with David Jefferies.

open. line is Your

David Windley

believe that the to questions. Thanks Syneos contributed activities Hi. bookings I of that million first Did something Alistair, One hear year. Thanks. like I the I your saying my that the for caught in right? $XXX gentlemen. taking morning, half Good you

Alistair MacDonald

Yes.

David Windley

June, windshield when that And what’s help of you plus $XXX if slowing? what’s how the number saw of you’re the us close in million kind roll that bookings? enough that in climbed the I total -- us and so, that taking to. wins you amount had Can like about kind understand that forward Just talked gotten amount the is of that’s can now of you kind you to in a

Alistair MacDonald

into But conservative we did awards, you Syneos Yes, Dave. manner on that … Thanks, bookings because correctly. a take remember hear sure. very Yes, One

David Windley

Understood. Yes.

Alistair MacDonald

are bookings starting its when result we line we it's service and off of only … X-month window service work. take them lines, within into multiple

sits that million those presold, part you -- the is those in, that bigger there taken this So what $XXX to that those waiting within if elements we've while projects window. for almost a hit is like,

I think Jason, So, …? you

Jason Meggs

more Yes, there. Dave, color little to bit a add just

from what at to we talked the end-to-end perspective where Syneos One what So, we’ve is asset the in working an going we deals that on true -- end-to-end. June be as about we’re from look

over said into assigned, to $XXX they that really prepared strategy assigned, awarded, strategist bookings. and Clinical and articulated. we and how it's the deals greater end-to-end -- million million incremental get currently asset with asset an we're the an an in strategy of as starting work on and contract to we our articulated that have awarded, the that etcetera the remarks in $XXX The within they’re we than we’ve working helping not end-to-end certain and business it's terms get We Commercial been of to we're hopefully policy, under Alistair deal, their Syneos come deliver efforts to as pieces the and segments, that's where in is is will time. make project projects that of But One working

David Windley

Interesting.

Okay.

So the $XXX that still also incremental true that able is assume begun that the the speak that to -- $XXX been totally $XXX terms million quantifier? Is you've of amount of more that deals. part end-to-end talk is or there about you've million is in can you you of take what that to bookings million or into than the to I

Jason Meggs

number we bookings. and -- like come had June, it's Dave, on our I policy -- but of million needs --in has has little around of gotten it the this to Yes, it's where point million given right at of right bit exactly color $XXX around a the Yes. same the $XXX into we think our

David Windley

distinct Okay. numbers But …

Jason Meggs

Yes.

David Windley

million? two times $XXX …

Jason Meggs

Yes.

Alistair MacDonald

Yes.

Jason Meggs

right. That’s That’s right.

David Windley

you you've as but large is hunting at that getting about and Okay. about you year-ago of provider preferred ship the kind I'm gotten time kind in into Definitionally, ships, remembering those about about this traction licenses talked that year-ago preferred a Alistair, a a than provider pharma talked less little and clinical you talking breaking of … are the

Alistair MacDonald

Yes.

David Windley

more a preferred … or I clinical partner. What provider the am over sounds hear I I that Am hearing today little bit describing of not right old partner. more you interpreting?

Alistair MacDonald

No, I one. good think is interpretation you’re a

this is than hunting So more a license.

David Windley

sorry, -- go And ahead.

Jason Meggs

going that in last June more awarded. partnership just to terms were that, we what about this like was to the is I talked we add oncology of that

book we're is we this and to sight this line we for providers have projects have of -- taking will two will work and the of a we So company. one be where of

David Windley

Got it.

easy will it us to Thank the Last and would give one. quickly. us last my be -- Kinapse that you you. question Okay. commercial, you inorganic Could and make mind contribution, on the

Jason Meggs

Yes, still so organic the we -- I quarter mean, Dave we in single-digit were high excluding growth, Kinapse.

David Windley

Okay. Thanks.

Operator

you. Thank

Our next from with Erin comes Wright Suisse. Credit question

line open. is Your

Erin Wright

Great. ahead Thanks. the hiring should guess about relationship? In And from anticipate at environment light the win, of overall the of large contribution moment? we should new clinical more we meaningful hiring up stepped think I that how

Alistair MacDonald

Yes. you off I the start Paul will a then morning, you bit of Erin. Good and detail. will more give

about talk So, general be they we as demand recruit well, therapeutic going let's there might than harder yes, traditional the because some are the and geographies There others more areas, there's environment. hotspots -- not supply. always, just are to specific generally

is China, to market are CRO where opening up probably Japan, we talking which is for really single places there every upscale. So think the clinical I same the work, out

is side been organizational of these on taking have think streams, recruiting start have up of got already systems the the work those running. they some connectivity between you little personnel the operational. yes, of our cost kind that On last help create systems and will you've are bit. and appropriate the of us because I we ensure the that of key stand in is partnership, care in a already that the actually have ahead be both to views over associated things to place up, some one, But When

Paul, add delivery purely around new our So to operational for it more be to heads anything you will want that? purposes.

Paul Colvin

I appreciate the question.

around you’ve is sites. really important pressure performance quarter partnership think this That you to the at as is remember with you need to startup what you I strong up that view and was a you that's the And the the you business staff what globe. do startup activating staff as gives got you’re initial startup six of with least into right got really I in we months staffing, ramping any think valve will there phase, steady seen your up. when

as internal forecasting go the we but strong to of pipeline see very and that nice a will got way be what’s engine we we a from will this we’ve have forward. coming run So out, partnership

I So worry about that. don't

Erin Wright

Okay.

can helpful. that consulting in across out you. components Okay. That’s of well guess, traditional you Thank some And trends versus commercial, CSO as the I parse would well? it as the growth offering whether advertising more then in be as

Jason Meggs

can Erin. will then This start Jason. I Yes. and is add. Michelle Hi,

educators, that One some a types Michelle seeing little quite your -- work it's -- other are we moment omni-channel CSO little Solutions. deployment different your growth the as that's etcetera. the solutions of where right different strongest the traditional but but that -- you at a businesses well. nurse strong growth growth with bit as the The in across what business, that now other But pieces one evolving can well. also area, So profile MSLs, is more just really in bit is a growing underneath color, add other into tied specialists And the across of from of the field non-personal is promotion reimbursement have and teams

Michelle Keefe

opportunities of also would are And absolutely. more that we’re much our is integrated. add what that I Yes, winning

business difficult into which slot almost it right it's to unit, is. So a

that that market, depending might to that communication maximize of call what at frankly solution market going different time performance the We’re responding we brand. a on what of in we with when include omni-channel deployment are that needs solutions. include come an an opportunity integrated and going of RFP And may is as believe we variety things it to the center, respond,

and business one I is business say being over services than you for that think heard quarter one win us now of XX% our our think last so I more unit. And more more with of

seeing that’s a we think really lot so I we wins, more wins. And really are our when look integrated at

we’re we a believe board, -- to Syneos is be the success integrate what that important, able Health will of big to so able customer. capabilities that’s across And been the part solutions deliver of best-in-class be to our our for that’s because

to just reinforcing in very offer. we’re how we’ve interested that’s So what that. are Customers

Erin Wright

Okay, you. Thank great.

Operator

Thank you.

Our comes William Kreger from next question John Blair. with

Your open. line is

John Kreger

Thanks you’ve where since reflect Paul. seems much. can integrated clients, bit Syneos kind really the the a is Paul, offering A where of a sense? to the most client been type of make type very Hi. on business One -- a offering question more little you certain resonates the certain there for for of just with it type project there

Paul Colvin

I to Well, think it cross gets -- we’re segments. starting seeing it

think even it mid bringing starting that we started, capabilities pharma going we’re is I first see in we assets the more and to I the we of pipelines integrating outside what What their internal be earlier are was to assets, life think cycle development. thought kind own cap. can large our is they wanting and help small to bring or to in from they’re about as think developed see though

can pharma behavioral going the across sectors, of to that I’ve with value cycle as been a think And in interest patients combination where commercial that moving information in that think the together add life that something earlier point particular they as think I bringing in see sector that information, think happy is really you much of data about large clinical development. development, forecasting that see seeing I forward. but into we're So particular,

John Kreger

business, clinical versus Got what think trending tell about was how traditional? work type guys you is that FSP does said the is I right? it. And for that Thanks. us driver a that And mix positive

Jason Meggs

Hi, John. Yes.

you The where So helpful, come to mix terms underlying together more see. in it we’re is under in on mind FSP is was reimbursable well that’s there expenses. keep of service, versus as a full full starts profile has side, When positive XXX used sort basis, quite think bit which about that strength of do seeing clinical, FSP in but the minimal margin we’re the correct. to separation service

John Kreger

Okay.

Alistair MacDonald

want to -- John, I Yes, this I is think Alistair. just

hybrid. kind one got Just are service system. the seeing large top to add very integrate and of us, in as the with certain full are across it of for to think areas customers, of We've more about, us that kind our FSP I because penetrating functional we thing helps sitting well we works it more the

So style at comparison we’re able margin pretty service as to well. full in from that good work with drive

one of whole points strong the clinical the can So, this two. an That’s really we FSP we strong was full see XXX hybridize is big really sites has FSP, of also aspects service, of kind FSPs and It's payments, doing clinical see it. create as might organization about. -- of merger then around why the the other investigator well, not the those project hybridization in just bought the monitoring management, the all data you it's clinical management, pieces typical other all all that into

scale when hybrid a lot are bigger in it doing that So makes and bigger we more like efficient a manner.

John Kreger

Very helpful. Thank you.

Operator

our Thank you. Muken Evercore. And next question comes with from Ross

open. is line Your

Ross Muken

Congrats. guys. morning, Good

for activity biotech commercial of more of and with with all are -- sort that color new uptick just trends specialized on large sort also us the the we calendar sort kind business? we’ve fundraising that’s therapies, of in how the base, just impacting lot of little a the in given of of some within again the the Just give guide, bit of client seen

Alistair MacDonald

-- can We you -- Can the broke at say Ross. also right you you beginning. ask Thanks, again, first the please. sentence

Ross Muken

the So the that’s the on demand, side. just and side What new fundraising, clinical all for given more commercial in of therapy, on in how of business? launches trend then gene more on specialized terms of of the the sort right, both the translating the meaning of base just of terms that's customer age biotech, given the part the that

Alistair MacDonald

Yes, okay. Yes, sure.

the because seen that upwards So the they that market, terms target market patients. market these specific bringing more you’re that, we what can out point And think in you pushing before. more side. it's I start [ph] We’ve the I like the than who think drug might we’ve brings. through the gene seen on The patient's people I the And those science think actually higher. value a be healthcare price on healthy benefits is that constantly penetrate to can the we the sure therapy, make take biotech and the more of the patient, this and clinical new that fact progression to have repairing the specialty on is it have the life the what reimbursing we that price more provider offering, is to to more point the when drugs and and of and the it, impact benefits integrated of overall it's

excess material I capabilities, of kind the omni-channel, access launch mostly field but to services, the nurse that of that of force consulting margin. HEOR support nicely more commercial sales in for better traditional think market the MSL suite in margin that plays group, or smaller very higher our drug of then common preparing value treatment, it that educators for you specialized, and team, is terms which of type type but then

that have able plays who nicely very developing That ongoing science, doing, level infrastructure the think we provide specialty shift infrastructure. is any a very small are high with I to shift don't fits of what are particularly were and gene as that that who therapy organizations nice. into we cell to all

the it plays very commercial Michelle, So side? things I think any nicely. for us, that on

Michelle Keefe

what do think we really our development, it's I of opportunity I right, there. product that’s how about seamless is think really the continuity

difficult, opportunity population to with an area that’s this really thinking us going the what’s in seeing we’re they they’ve have because not the tend the just these see patient to patient patient, to in with it's access biotech but all product and caregiver to have what easy and on really they to also that quite is to through really we’re right. going sector, identification support frankly smaller, sometimes patients. the resources and well, the and the those need some ensure It's to be that way that people doing they think not and understanding them, I that identify the that patient work medicine of take

really market. going So, it's us development, that’s thinking their is gets just really continuity on, when think the it in product take a patient what of therapy, ultimately value on the that market, to to I not the we but that what bring to through the unique support seamless going through

Ross Muken

Great. Thanks, guys.

Alistair MacDonald

you. Thank

Operator

you. Thank

Research. Wolfe from comes question with next Our Stephen Baxter

open. is line Your

Stephen Baxter

for hoping revenue year-to-date what little the from the obviously It quarter, looks Thanks. at growth implies that and question. versus in pretty outside customers seeing to where flattish broader like the more what could of the the I other first bit your on largest top a preferred happen looks of the that for growth your top on overall you’re sort XX and a adding in is it parts return of some I like And robust. was moderating seeing revenue the contrast down for you’re needs absent Thanks concentration a which was customers, to drag you Hi. was XX than that the what of end top relationship, show know basis this but line? you’re smaller to your spectrum?

Jason Meggs

others will chime then I in. start and can Yes,

growth in commercial I customers portfolio we right. we’re well terms in significant talked business, you’re on the top the specifically there. and side the is significant strong mean, So and remarks, seeing of really and about pipe. both the prepared and of growth Pipeline of revenue the this SMID outside

the plays is up, SMID side, right. story INC through On to legacy business, etcetera. trials well gene business same, cell complex the clinical what’s grew The and the coming therapy,

continuing in in bit half I and There second on expand little that's as are about in and if partnership well. pipe that side clinical that the And and you on on businesses we currently focused revenue we're XXXX. Paul, new addition the large Michelle, to beyond have on are know, the pharma on in commercial? the don’t a existing We would that we the to what both have. that opportunities see to customers talk

Paul Colvin

from One that obviously new won to to Thanks, on. partnership take there's went backlog. is going we few is Jason. mean time a a the think that I ramp, doesn’t things an perspective, I with clinical Yes. come existing

So think second half a ramp. again, as Alistair we and see I has mentioned, that's more 'XX into that of 'XX of as

see large as of what it's they that this you there pipelines a those a others will actually across play together, in look it we've We that as is put part delay. but that some large upside, the X through through come it half through the of 'XX. our we say of see some Phase we into first reprioritization other out X, If partnerships, will will don't pipeline through, be a consolidation seen be second long-term not as you and cycle something to I partners where the churns would And from half. into It a Phase they’re assets of we've and 'XX just is pipeline they couple Phase is seen third will those is, go those revamping X their see time-to-time.

combination of things. I So those it's a think

Stephen Baxter

great. Okay,

Michelle Keefe

I talking is we’ve will I purposeful been on we’ve the commercial commercial diversify our the mean, from important first think is, was perspective, backlog. I that. share how about very to So and thing to focusing it been business a that

continue we’ve are that. we in think our on that top to From I multiple customer so to focus the and top customers. perspective, backlog of And opportunities with with pipeline pleased we’re going the a diversification

our think and continue management it clinical So really think I on top be can that. the we’re investment confident focus to that commercial we key going scratching that’s and bring area to I customer, to on that we’re our account strategy an in that together the and surface leverage to power

think I us opportunity forward. huge moving a for that’s

Stephen Baxter

Great. quick guidance. a side growth you Thank follow-up. on pass-through tell to And then your was hoping relative the just revenue impact, the I could us clinical you.

understand your in as service for to metrics? whether So I’m better with basically trying clinical in or was the revenue with guidance component line the consolidated line Thanks. also

Jason Meggs

Yes.

than said So we there, had expenses reimbursable as did the anticipated. -- faster we our grow

of guidance the at anticipated. that look what pretty you much had outside on bang across we were we If

Operator

you. Thank

Morgan. Our next J.P. comes from with question Tycho Peterson

is open. line Your

Tycho Peterson

of for up next I will start a X, is pharmaceutical more given frame? that like can the of to the earlier see of EBITDA other we essentially sustained over year-over-year. for begin whether more XQ time just large XX guys. guiding question. It the year-over-year the guidance. one EBITDA Thanks flat a you’re Hey, obviously XQ quick margins improvement. looks wondering just year-over-year Jason, was little going for to bit follow-up on and contract stage these thinking over in pick here, months projects ramp strategic that some to XX

Jason Meggs

Yes. Hey, Thanks. Tycho.

one the in last did benefit from QX here we second of to as was that 'XX that a in the mentioned relative is -- of we the prepared XQ. $X million So have forward to the remarks half nuance pull year

look for XX XX future same we're that, talked year-over-year QX longer-term, right, I we XX, years. think original normalize in you how about And margin still XX about XX EBITDA margins is then our can seeing -- in basis we’ve points in when benefit the the on still guidance. say basis points and year-over-year. as of growth So are guidance grow we focused When revised targeting what the that to expansion you

So that. we're on still focused

Tycho Peterson

Got pick on quarters as quarter-over-quarter trailing here seasonality the And sort in to of certain Clinical like both follow-up the decline? it. Selling just then one awards. by the that XX% that It look or out well regular like X%, in net so, anything calculation? as XX-month read Solutions quick lumpiness drop Is down or as or there of is

Jason Meggs

Yes.

is on side, the keep we had in want with So Clinical the book-to-bill X.XX right range to we it a line quarter, which the in in.

basis. on had 'XX QX XXX we a are a where strong X.X We ASC very lapping

So pressure there. that's the you see

bit things little we’ve the of easier. talked last Looking about you are forward to with the look and year, if the QX comps all

from the the creeping XX-month. focused we are X.X half year of second on that that trailing backup in So

strong adjustments On quarter in some we The year, quarter of because is range impacts into in in an see good revenue little full-year we but first built that our revenue the We risk the quarter -- impact really half side, that bit. first had we see, a does that the a the guidance we news last little did seasonal again. of uptick typically it impact that forecast, Commercial saw the second the that book-to-bill doesn't on bit Commercial.

Tycho Peterson

and on a much, Thanks Got congrats it. guys so solid quarter.

Michelle Keefe

Thank you.

Jason Meggs

Thank you.

Alistair MacDonald

Thanks.

Operator

Thank you.

Barclays. with Meehan Jack from comes question next Our

Your line open. is

Jack Meehan

wondering international new business provide there, morning. there in any were side? updates going was you just on the China? if How is could Good I you. development Thank notably

Alistair MacDonald

Yes. Jack. strong in so in Good we’ve Yes, BD team morning, Asia PAC pretty out general.

we what and they’re they I local -- see that winning. think global. It's both

startups out delivered So we’re bios come globally from etcetera, biotech seeing PAC we of Asia projects for and them.

in -- in biggest fact, came our single I that In in XXXX award style. think

globally. very not from the region, but locally said work as also delivering and just winning we more see So it important both as I work,

Jason Meggs

I as being Jack, to that, see Yes, the add mean, just clinical strongest available. to the in Asia we market PAC growth market

important we're and we’ve So end and focused scale that on a reach end-to-end we have more perspective. a Europe that said, look commercial, on there, more you But because that you right, commercial and from have the footprint relatively stay that's -- Alastair very including at a market becomes that scale front more when strong but we're and is equally -- and BD. it good focused Europe as in these deals and that that

Alistair MacDonald

And to strategically to the want just to wanted I we’ve One. provide thing actually, that one all Well, include Syneos be customers are to able add wherever same services always we geographically.

a no in think in coming Syneos So in no launching that supported have a West we've seen they by infrastructure Asia, biotech investors the in companies, West. interest drug lot as the have of of the out experience because One well as

that market. compelling becomes it very in a model So

Jack Meehan

you. Thank research on Great. I core Jason, also want to side. follow-up the

the pass-throughs, is there just is timing what nice was versus to maybe provided? you was core a was wondering -- out revenue you performance think then pretty drove which had if the obviously could and way parse obligation a with quarter. in be You those I mix upside what the there about

Jason Meggs

Yes, I a our it other well so basically we had quite mean, than -- growth the we guidance, reimbursable -- was achieved faster -- expense did bit we aloof, quarter. in

through good QX. So talked put that of down, we us slowed little QX saw that about bit in pressure then in that was there margin see we of items a and some a we timing the on what underneath come did that

first they so about there you these it think it, growth the lag, QX half second had then look timing move your and of help if can in that So in QX, at just in some a you QX, items plot terms hurt QX half. can around project lifecycles, reimbursables, in QX out strong,

Jack Meehan

just guidance. could to And maybe with if for in just market, update the you’re interest you be of squeeze in assumption bit about terms obviously Could Fed, related in can think might more, and timing also related I when to just give just you there that. a the do you how one us little upside an interest be in rates, thinking Okay. the

Jason Meggs

so late May, in our term out is we gave in bonds, we of call X.X% gave the bonds draw the we finalized date. that that Jack, what first we said already previously. there with Yes, A can we high the had March the refinancing where loan range where we October, feature guidance have delayed yield When we early consistent have the take in

If there, continue held. So see on we early we're that. too into that’s baked some all go XX%, we to guidance, call benefit, could variable original which and rates just to but our XX% of down

Jack Meehan

Thank Okay. you.

Operator

you. Thank

next question with Hooker comes KeyBanc. from Our Donald

Your line open. is

Donald Hooker

Great.

makes guess complexity move just to ahead, full able the you sense the question is in Just I full of markets quarter, earlier curious looking your might pipeline think looking a kind trials think structural arrangements. of if of where kind feels more in towards service shift of terms some comment going, be It the an service, dovetailing the was mentioned mix, kind of of given like so sort I'm coming off of which a at there I there market? to I some you that’s

Alistair MacDonald

will Yes. start Paul. hand to and I

other this you years in on a the depends psychology more an it clinical pharmas, think oscillation get on over precision how we than there's the full I But a FSP thing an the we organizations want from project. seen we’ve move, seeing think particularly a rather around in organization, mean, outsource. kind lot it more depends of efficiency I -- service hybrid larger as I are of as shift. of well kind outsourcing

the the know mid you market guys seeing I combination bit to of towards think is the both. larger some of best is of small as well. where get you best a a in very pharmas And we're hybrids growing --

they -- to don't you the scale they yes, have FSP, it. because through don’t use So, outsource

any Is Paul? there help you that, to into different service So the got to drive full market.

Paul Colvin

well that’s think said. I No,

They’re to in we me are through, small contract, efficiency more what of bespoke to going you that’s agree my can we’re across that’s custom do I seeing still entire a think models where flowing model to I strong be a biotech of most bit hybridized allow think portfolio group. seeing full service build shifted the to but mid work. growth drive to so going at I predominantly that

I I uniquely continue so because size that, in across both looking it's to think going think model the the positioned scale full efficiencies to we're and and entire that for have the be service, we portfolio. the FSP do to hybridized

Donald Hooker

sort guys, you’re Got What general you elaborate for -- segment? few market I targeting what’s -- ratio over know of we a the backdrop you. do for the And you’re for if strength of just next a maybe willing you? don’t -- given to much you sort quick what how how the follow-up, book-to-bill that quarters here of do contemplate Clinical Solutions the

Jason Meggs

it Yes, is Jason.

unchanged. we're So

X.X targeting to are X.X trailing business. We on for a XX-month basis the Clinical

Donald Hooker

Super. Thank you.

Alistair MacDonald

you. Thank

Operator

Thank you.

Dan with Our UBS. comes next from question Brennan

open. is line Your

Daniel Brennan

kind a And there. number, regional think you’re to relationship. about category, guys. taking I to sizing Great. know the announced, clinical back I to win anyway terms kind therapeutic a lot of color go reference the you for going there frame global to more the so give that just questions, Thanks not large of Thank to of was in get Any hoping you. focus? impact? the trying or

Alistair MacDonald

you -- Paul, to well, me start. want Yes. let

we in is was not Paul, us easier of -- exclusively last projects that This pretty varied we to big the oncology. bit a which more broader one to of we …? match So, roll therapeutically mainly well year obviously orientation, global, build therapeutic which available one, all the can previous which than I relationship and as off in -- for teams they makes time certainly talked anything enables terms well, a because bit about therapeutics. -- finish its therapeutics a us, new actually think diverse almost little

Paul Colvin

I Yes, would agree.

going to mix be it's therapeutic think I area. a

weighted heavily it's going As portfolio versus in another. pretty that also not That I think to be one balanced. is region

weighted heavily in we're of the another norms in area outside So or I being that seeing don’t industry. see the one it

Daniel Brennan

been wondering what pricing know I the competitive really that and Maybe seeing of on to date addressed just good, pretty trend? certainly the Okay. is think kind question on and had environment. was you’re of I kind quarters pricing second but just

Alistair MacDonald

Price commercial or behavior we’ve or out we’ve mean market. any than commercial has strange normal. -- I clinical the there? pretty seen In other been in

Jason Meggs

Yes.

Daniel Brennan

of terms -- there positive just drug price relationship of And or concerns, been your in in your with or that? negative terms timing of in in any like has with marketplace things noise decision with terms whether of making the impact impact overall the terms in customers

Jason Meggs

is a no. side Dan, -- think I just a on it clinical it's

for that side commercial the where driving access, on sure. stuff health of in market force, the particularly consulting think its economics, I kind

Michelle Keefe

where and So, are the I right, one on whatever that's that land. they’re our helping be that’s to competing do policies the of with we’re is address customers help in, that, positioned to we always think regardless of marketplace going uniquely to with and there things them them anything

in expertise they relations, patient look through diseases public have access do access ensure thinking that value have. what really different. reputation -- be like risk in a \s need the take We world could medicines to the and value pricing you in management, where they will that that How for develop

And so these are are things going -- these on.

them good to partner in customers perspective All where and in. service our lands, they a land, of think going we’re to I but us whatever have idea support it's environment wherever operating to position with no from end it up a right,

Daniel Brennan

Great. Well, congratulations. Thank you.

Alistair MacDonald

Dan. you, Thank

Michelle Keefe

Thank you.

Operator

with Baird. from question a we’ve Polark Michael And

open. Your line is

Michael Polark

Hey, good morning.

interest, X tuck-in new updated that acquisitions XX like me. say additional expectations. would appetite for Kinapse areas deals, next great. to met Curious months. we on Thanks. largely something over, Just Seems an has for like one for be the comment Should of expect

Alistair MacDonald

customer Mike. want market. mean, lot still we Good And We're very the But high. down of is Yes, opportunistic. debt. the seeing a moment the to Yes. at to assets morning, is deployment paying product I stay brought multiples being

scope have it really lot So The for be us. that we the we to a have a got scale and that boxes something covered. strategic lot ticked

with an really of the the this feel gaps that only time, that of set we being -- in way for find of one be to that multiples in asset would multiples they the bat thing go interested first be So etcetera, would to are. that have we [ph] that that be are really we remaining terms the the we

Michael Polark

you. Good. Thank

Alistair MacDonald

Thank you.

Jason Meggs

Thanks, Mike.

Operator

to I And any back like further to not the any showing I’m you. would Alistair Mr. questions. MacDonald call remarks. Thank turn for closing

Alistair MacDonald

Thank you.

the we’re the growth of strong XXXX remainder very we with throughout believe quarter. and in our I positioned pleased beyond. to growth well are second drive So

RFP opportunities by solutions. strategic and Our investments very pipeline customer flow and in of integrated robust, interest driven strong outsourcing remains our

and So be thank your today Thank investment attendance and and you you. for great day Syneos have in good. Health your for very much and interest a

Operator

you thank This for in gentlemen, and Ladies concludes participating today’s conference. the program.

have all You may disconnect. Everyone day. great a

Syneos Health (SYNH) 6 Aug 192019 Q2 Earnings call transcript